USPTO Examiner LOCKARD JON MCCLELLAND - Art Unit 1647

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19229468ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOFJune 2025November 2025Allow610NoNo
18924707VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATIONOctober 2024February 2025Allow410NoNo
18650019PHARMACEUTICAL COMPOSITIONS TARGETING IMMUNE-MEDIATED PROCESSES IN NEURODEGENERATIVE DISEASEApril 2024October 2025Allow1711NoNo
18618991FORMULA OF NEUREGULIN PREPARATIONMarch 2024March 2026Abandon2410NoNo
18444102METHODS FOR INHIBITING DIAZEPAM BINDING PROTEINFebruary 2024February 2025Allow1220NoNo
18396206FLT3L-BASED CHIMERIC PROTEINSDecember 2023December 2025Abandon2401NoNo
18534366USE OF THE EXTRACELLULAR DOMAIN OF TRANSFERRIN RECEPTOR 2 FOR THE DIAGNOSIS OF DISEASEDecember 2023February 2026Abandon2621NoNo
18504723METHODS OF TREATING AN EYE DISORDERNovember 2023September 2024Allow1010NoNo
18497432FOOD-ALLERGEN SPECIFIC ANTIBODY COMPOSITIONSOctober 2023August 2024Allow1011NoNo
18496472Use of a VEGF Antagonist to Treat Angiogenic Eye DisordersOctober 2023July 2024Allow810NoNo
18491682HUMAN CD163 ANTIBODIES AND USES THEREOFOctober 2023October 2025Abandon2420NoNo
18376196INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINSOctober 2023March 2025Abandon1710NoNo
18367444AN AQUEOUS PHARMACEUTICAL FORMULATION INCLUDING A VEGF RECEPTOR FUSION PROTEINSeptember 2023September 2024Allow1210NoNo
18465145NUCLEIC ACIDS ENCODING PEPTIDES THAT BLOCK BINDING OF a2d-1 TO GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERSSeptember 2023August 2024Allow1110YesNo
18446018METHODS OF EXOGENOUS DRUG ACTIVATION OF CHEMICAL-INDUCED SIGNALING COMPLEXES EXPRESSED IN ENGINEERED CELLS IN VITRO AND IN VIVOAugust 2023March 2025Allow1910NoNo
18353623COMPOSITION COMPRISING RECOMBINANT GPIBA RECEPTOR PROTEINJuly 2023August 2025Allow2520YesNo
18219336ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOFJuly 2023March 2025Allow2011NoNo
18344786VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATIONJune 2023November 2024Abandon1710NoNo
18341278CXCL10 BINDING PROTEINS AND USES THEREOFJune 2023April 2025Allow2111NoNo
18339061METHODS OF TREATING AN OCULAR DISEASE OR DISORDERJune 2023April 2025Abandon2111NoNo
18332068METHODS FOR REDUCING MIGRAINE FREQUENCY IN A SUBJECT IN NEED THEREOFJune 2023October 2024Abandon1610NoNo
18331901Antibodies Targeting Integrin Beta-2June 2023December 2025Allow3000NoNo
18328960Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using SameJune 2023October 2024Abandon1610NoNo
18165614ANTI-PAR2 ANTIBODIES AND USES THEREOFFebruary 2023June 2025Allow2811YesNo
18055642VEGF/DLL4 BINDING AGENTS AND USES THEREOFNovember 2022August 2024Abandon2101NoNo
18048345COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIESOctober 2022April 2024Allow1710NoNo
17996120CCL24 INHIBITORS IN THE TREATMENT OF COVID-19October 2022December 2025Abandon3810NoNo
17958710METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONSOctober 2022June 2025Abandon3310NoNo
17955111ANTIBODIES BINDING SPECIFICALLY TO NT-PROBNP AND USE THEREOFSeptember 2022October 2025Allow3610YesNo
17935261METHODS FOR WEIGHT REDUCTIONSeptember 2022December 2023Allow1521YesNo
17946921ANTIBODIES TO L-TYPE VOLTAGE GATED CHANNELS AND RELATED METHODSSeptember 2022April 2024Allow1911YesNo
17929824REDUCING ECZEMA AREA AND SEVERITY INDEX (EASI) IN SUBJECTS WITH ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODYSeptember 2022February 2026Allow4210NoNo
17822705COMBINATION TREATMENT FOR CANCERAugust 2022February 2025Abandon3011NoNo
17822701RADIOCONJUGATES TARGETING CD33 IN THE TREATMENT OF SARCOMASAugust 2022November 2025Allow3811NoNo
17883434RADIOCONJUGATES TARGETING CD33 IN THE TREATMENT OF CANCERSAugust 2022December 2025Allow4012NoNo
17813016METHOD FOR TREATING OR ALLEVIATING ENDOMETRIOSIS WITH IL-33 ANTAGONISTJuly 2022November 2025Abandon4010NoNo
17811642THERAPEUTIC ANTI-CD40 LIGAND ANTIBODIESJuly 2022January 2026Allow4211NoNo
17840557ANTIGEN ANALOGUE FOR CALIBRATION OF IMMUNOMETRIC DIAGNOSTIC ASSAYSJune 2022June 2024Allow2420NoNo
17783528CXCL10 BINDING PROTEINS AND COMPOSITIONS THEREOFJune 2022March 2023Allow1000YesNo
17830298LONG-ACTING VEGF INHIBITORS FOR INTRAOCULAR NEOVASCULARIZATIONJune 2022September 2025Allow4021YesNo
17663675ANTI-C5 ANTIBODY COMBINATIONS AND USES THEREOFMay 2022May 2024Allow2410NoNo
17740744Use of a VEGF Antagonist to Treat Angiogenic Eye DisordersMay 2022November 2022Allow610NoNo
17725608PEPTIDE MIMETICS OF DKK3b AND METHODS OF USEApril 2022November 2025Abandon4201NoNo
17724399METHODS OF TREATING COLORECTAL CANCERApril 2022September 2024Abandon2911NoNo
17803251Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods ThereofApril 2022January 2026Allow4511NoNo
17695592ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN BINDING FRAGMENTS, PHARMACEUTICAL COMPOSITIONS AND USESMarch 2022June 2025Allow3910NoNo
17684057METHODS AND COMPOSITIONS FOR INCREASING THE DOSE OF A CHEMOTHERAPEUTIC AGENTMarch 2022February 2024Allow2410NoNo
17633351INHIBITION OF METASTASIS DEVELOPMENT BY NANGPTL-4February 2022September 2025Abandon4301NoNo
17628056GLYPHOSATE BIOSENSORJanuary 2022December 2025Allow4720NoNo
17578147NEUREGULIN BASED METHODS FOR TREATING HEART FAILUREJanuary 2022June 2024Allow2910NoNo
17576886COMPOSITIONS AND METHODS FOR TREATING HEART FAILUREJanuary 2022April 2024Allow2710YesNo
17570248HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOFJanuary 2022February 2024Allow2510YesNo
17558451POLYPEPTIDE COMPOSITIONS AND KITS FOR TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTIONDecember 2021June 2025Abandon4230NoNo
17546801ANTI-IL12RB1 ANTIBODIESDecember 2021December 2023Allow2411YesNo
17596145CHIMERIC AUTOANTIBODY RECEPTOR (CAAR) THAT BINDS AUTOANTIBODIES TARGETING THE CENTRAL NERVOUS SYSTEM IN NEUROLOGICAL AUTOIMMUNE DISEASEDecember 2021January 2026Allow4911NoNo
17615474ACTRII-BINDING PROTEINS AND USES THEREOFNovember 2021October 2025Allow4611NoNo
17615000G12-SPECIFIC DESIGNER RECEPTOR EXCLUSIVELY ACTIVATED BY DESIGNER DRUGSNovember 2021December 2025Allow4911YesNo
17526929LONG-ACTING VEGF INHIBITORS FOR INTRAOCULAR NEOVASCULARIZATIONNovember 2021April 2022Allow510NoNo
17525169SOLUBLE LIPIDATED LIGAND AGENTS FOR TREATING EYE INFLAMMATIONNovember 2021March 2024Allow2810NoNo
17510271EXTENDED RELEASE OF NEUREGULIN FOR TREATING HEART FAILUREOctober 2021September 2024Allow3511NoNo
17508759ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOFOctober 2021July 2025Abandon4501NoNo
17604891Netrin G1 PolypeptidesOctober 2021January 2026Allow5111YesNo
17604495SIGLEC-BASED CHIMERIC POLYPEPTIDES AND USES THEREOFOctober 2021December 2025Allow5021NoNo
17604711IPILIMUMAB VARIANTS WITH ENHANCED SPECIFICITY FOR BINDING AT LOW PHOctober 2021July 2025Allow4511YesNo
17601321ANTI-CD25 ANTIBODY AND APPLICATION THEREOFOctober 2021March 2025Allow4210NoNo
17492649AFLIBERCEPT FORMULATIONS AND USES THEREOFOctober 2021February 2024Allow2910NoNo
17599481METHODS OF REDUCING LARGE GRANULAR LYMPHOCYTE AND NATURAL KILLER CELL LEVELSSeptember 2021March 2025Abandon4101NoNo
17599454TESTIS DEVELOPMENT RELATED PROTEIN ANTIBODIESSeptember 2021July 2025Allow4611YesNo
17485067Methods Of Treatment Of Keloid Using An Anti-VEGF AgentSeptember 2021December 2023Abandon2710NoNo
17442608COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITORSeptember 2021January 2026Allow5221YesNo
17441028ANTI-ALPHA BETA TCR BINDING POLYPEPTIDES WITH REDUCED FRAGMENTATIONSeptember 2021March 2025Allow4210NoNo
17438653PRAME BINDING MOLECULES AND USES THEREOFSeptember 2021September 2025Abandon4811NoNo
17472051NUCLEIC ACIDS ENCODING ANTI-TREM-1 ANTIBODIESSeptember 2021December 2023Allow2710NoNo
17472302ANTI-TREM-1 ANTIBODIES AND USES THEREOFSeptember 2021September 2023Allow2510NoNo
17435370STABILIZED EXTRACELLULAR DOMAIN OF CD19August 2021December 2025Allow5121NoNo
17459556THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDESAugust 2021April 2024Abandon3201NoNo
17434247ANTI-CD6 ANTIBODY COMPOSITIONS AND METHODS FOR TREATING LUPUSAugust 2021April 2025Abandon4310NoNo
17434340ANTI-TNFR2 ANTIBODIES AND USES THEREOFAugust 2021July 2025Allow4611NoNo
17408768NOVEL RECOMBINANT BI-FUNCTIONAL FUSION PROTEIN, PREPARATION METHOD THEREFOR AND USE THEREOFAugust 2021March 2022Abandon711NoNo
17407111COMPOSITIONS FOR DISEASE TREATMENTAugust 2021March 2025Abandon4201NoNo
17430396ANTI-PD-L1 ANTIBODY AND USE THEREOFAugust 2021December 2024Abandon4001NoNo
17430705CD1A ANTIBODY-EXPRESSING CAR T-CELLS FOR THE TREATMENT OF CD1A-POSITIVE CANCERAugust 2021September 2024Allow3700NoNo
17399364MONOCLONAL ANTIBODY AGAINST SPIKE S1 PROTEIN OF SARS-CoV-2 AND USE THEREOFOFAugust 2021October 2024Abandon3801NoNo
17399367MONOCLONAL ANTIBODIES AGAINST SARS-CoV-2 NUCLEOCAPSID PROTEIN AND USES THEREOFAugust 2021October 2024Abandon3801NoNo
17397221TREATMENT OF HODGKIN LYMPHOMA USING AN ANTI-PD-1 ANTIBODYAugust 2021January 2025Abandon4130NoNo
17396235METHOD OF PROMOTING WOUND HEALING BY INHIBITING CCR3August 2021September 2024Allow3811YesNo
17384070Methods for Treating Angiogenic Eye Disorders with High Doses of VEGF Receptor Fusion ProteinsJuly 2021August 2023Allow2510NoNo
17424591HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATIONJuly 2021June 2025Allow4711YesNo
17379968ANTI-TL1A ANTIBODIES AND USES THEREOFJuly 2021October 2025Allow5111YesNo
17420251HIGHLY MODULAR BIEPITOPIC AND BISPECIFIC CAR-T CELLS FOR CANCER IMMUNOTHERAPYJuly 2021July 2025Allow4811NoNo
17417603CONFORMATIONAL EPITOPE OF HEPATITIS B SURFACE ANTIGEN AND ANTIBODY BINDING SPECIFICALLY THERETOJune 2021December 2024Abandon4201NoNo
17416958PHARMACEUTICAL COMBINATION OF ANTI CEACAM6 AND TIM3 ANTIBODIESJune 2021September 2024Allow3910NoNo
17352892USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERSJune 2021December 2021Allow610NoNo
17054131METHODS FOR PROGNOSIS AND MANAGEMENT OF DISEASEJune 2021May 2025Abandon5411NoNo
17350958USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERSJune 2021May 2023Allow2310NoNo
17348438VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATIONJune 2021May 2023Allow2310NoNo
17347317INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINSJune 2021June 2023Allow2410YesNo
17298414CD40 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOFMay 2021December 2024Abandon4210NoNo
17330462PROTEINS COMPRISING CD3 ANTIGEN BINDING DOMAINS AND USES THEREOFMay 2021June 2025Allow4931NoNo
17327914NUCLEIC ACID MOLECULES ENCODING ACTIVIN RECEPTOR TYPE IIA VARIANTSMay 2021March 2023Allow2200NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LOCKARD, JON MCCLELLAND.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
2
Examiner Affirmed
2
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.8%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
49
Allowed After Appeal Filing
13
(26.5%)
Not Allowed After Appeal Filing
36
(73.5%)
Filing Benefit Percentile
38.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 26.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LOCKARD, JON MCCLELLAND - Prosecution Strategy Guide

Executive Summary

Examiner LOCKARD, JON MCCLELLAND works in Art Unit 1647 and has examined 1,198 patent applications in our dataset. With an allowance rate of 67.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 29 months.

Allowance Patterns

Examiner LOCKARD, JON MCCLELLAND's allowance rate of 67.4% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by LOCKARD, JON MCCLELLAND receive 1.23 office actions before reaching final disposition. This places the examiner in the 15% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LOCKARD, JON MCCLELLAND is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +37.8% benefit to allowance rate for applications examined by LOCKARD, JON MCCLELLAND. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 36.9% of applications are subsequently allowed. This success rate is in the 84% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 65.6% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 93.5% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 89.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 52.9% are granted (fully or in part). This grant rate is in the 53% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 10.1% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.7% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.